Neurology-focused Biogen and UCB are already rumored to be eyeing an Acorda buyout. But one analyst thinks a host of other major players could join their ranks.
The way Jefferies’ Michael Yee sees it, AbbVie, Allergan, Roche, Shire and Mitsubishi could all get in on the deal action thanks to their neurology infrastructure, Parkinson’s drugs that could complement Acorda candidate Inbrija, or both, he wrote in a Thursday note to clients. He expects Acorda to fetch $2 billion or more in a sale.
Inbrija, which Yee expects will win an FDA OK late this year, “is an attractive asset that could be easily integrated by several neurology companies,” he wrote, adding that he forecasts $300 million to $500 million for the product.
Of course, that’s assuming the FDA accepts Acorda’s application, but the company’s leaders appear “confident that NDA acceptance of the Inbrija package should occur any day now,” Yee wrote.
Activist hedge fund Scopia Capital Management, for one, shares Yee’s view that several biopharma players could end up on Acorda’s list of suitors. Back in August, it wrote to Acorda’s board that “we are highly confident that multiple qualified, potential buyers would be interested in engaging with Acorda,” while piling on the pressure to sell.
Acorda has apparently taken Scopia’s advice to heart. The company, which is scrambling to win an Inbrija thumbs up before knockoffs move in on key multiple sclerosis therapy Ampyra, has tapped Centerview Partners and MTS Health Partners to help it explore a sale, The Wall Street Journal reported last month.
By Carly Helfand
Source: Fierce Pharma
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.